Early detection of colon cancer: New tests on the horizon

Molecular Diagnosis and Therapy

Volumn 12, Issue 2, 2008, Pages 77-85

  Gupta, Akshay K ^a   Brenner, Dean E ^a   Turgeon, D Kim ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biomarkers; Colorectal cancer, diagnosis; Diagnostic Tests; Diagnostics

Indexed keywords

BIOLOGICAL MARKER; BONE SIALOPROTEIN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; GUANYLATE CYCLASE; MESSENGER RNA; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN;

BARIUM ENEMA; COLON CANCER; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; FECES ANALYSIS; FOLLOW UP; GENE MUTATION; GENE SILENCING; HUMAN; KIRSTEN SARCOMA ONCOVIRUS; MAGNETIC RESONANCE ANGIOGRAPHY; MASS SCREENING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; REVIEW; SIGMOIDOSCOPY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 42449155116     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256273     Document Type: Review

References (69)

1. American Cancer Society. Cancer facts and figures 2008 [online]. Available from URL: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf [Accessed 2008 Feb 25]
2. Meissner HI, Breen N, Klabunde CN, et al. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev 2006; 15 (2): 389-94
3. CDC. National colorectal awareness month: March 2008. Morb Mortal Wkly Rep 2008 Mar 14; 57 (10): 1 [online]. Available from URL: http://www.cdc.gov/ mmwR/preview/mmwrhtml/mm5710a1.htm [Accessed 2008 Mar 31]
4. US Department of Health and Human Services. The guide to clinical preventive services 2006: recommendations of the US preventive Services Task Force. Rockville (MD): United Health Foundation, 2006 [online]. Available from URL: http://www.ahrq.gov/clinic/pocketgd/index.html [Accessed 2008 Mar 7]
5. American Cancer Society. American Cancer Society guidelines on screening and surveillance for the early detection of adenomatous polyps and colorectal cancer: 2001. Altanta (GA): American Cancer Society, 2001
6. Hurlstone DP, Karajeh M, Sanders DS, et al. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia. Am J Gastroenterol 2005; 100 (6): 1283-9
7. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005; 97 (15): 1124-32
8. Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343 (3): 162-8
9. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005; 5 (3): 199-209
10. Rockey DC, Koch J, Yee J, et al. Prospective comparison of air-contrast barium enema and colonoscopy in patients with fecal occult blood: a pilot study. Gastrointest Endosc 2004; 60 (6): 953-8
11. Cotton PB, Durkalski VL, Pineau BC, et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 2004; 291 (14): 1713-9
12. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Ann Intern Med 2005; 142 (8): 635-50
13. Florie JJ, Birnie EE, van Gelder RERE, et al. MR colonography with limited bowel preparation: patient acceptance compared with that of full-preparation colonoscopy. Radiology 2007; 245 (1): 150-9
14. Florie JJ, Jensch SS, Nievelstein RARAJ, et al. MR colonography with limited bowel preparation compared with optical colonoscopy in patients at increased risk for colorectal cancer. Radiology 2007; 243 (1): 122-31
15. Vijan S, Inadomi J, Hayward RA, et al. Projections of demand and capacity for colonoscopy related to increasing rates of colorectal cancer screening in the United States. Aliment Pharmacol Ther 2004; 20 (5): 507-15
16. Gupta AK, Pretlow TP, Schoen RE. Aberrant crypt foci: what we know and what we need to know. Clin Gastroenterol Hepatol 2007; 5 (5): 526-33
17. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987; 37 (2): 147-51
18. Pretlow TP, Barrow BJ, Ashton WS, et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991; 51 (5): 1564-7
19. Yokota T, Sugano K, Kondo H, et al. Detection of aberrant crypt foci by magnifying colonoscopy. Gastrointest Endosc 1997; 46 (1): 61-5
20. McLellan EA, Bird RP. Specificity study to evaluate induction of aberrant crypts in murine colons. Cancer Res 1988; 48 (21): 6183-6
21. McLellan EA, Bird RP. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res 1988; 48 (21): 6187-92
22. McLellan EA, Medline A, Bird RP. Dose response and proliferative characteristics of aberrant crypt foci: putative preneoplastic lesions in rat colon. Carcinogenesis 1991; 12 (11): 2093-8
23. McLellan EA, Medline A, Bird RP. Sequential analyses of the growth and morphological characteristics of aberrant crypt foci: putative preneoplastic lesions. Cancer Res 1991; 51 (19): 5270-4
24. McLellan E, Bird RP. Effect of disulfiram on 1,2-dimethylhydrazine- and azoxymethane-induced aberrant crypt foci. Carcinogenesis 1991; 12 (6): 969-72
25. Magnuson BA, Carr I, Bird RP. Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid. Cancer Res 1993; 53 (19): 4499-504
26. Lam LK, Zhang J. Reduction of aberrant crypt formation in the colon of CF1 mice by potential chemopreventive agents. Carcinogenesis 1991; 12 (12): 2311-5
27. Corpet DE, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002; 43 (1): 1-21
28. Shpitz B, Bomstein Y, Mekori Y, et al. Aberrant crypt foci in human colons: distribution and histomorphologic characteristics. Hum Pathol 1998; 29 (5): 469-75
29. Roncucci L, Stamp D, Medline A, et al. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991; 22 (3): 287-94
30. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339 (18): 1277-84
31. Moxon D, Raza M, Kenney R, et al. Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population. Clin Gastroenterol Hepatol 2005; 3 (3): 271-8
32. Adler DG, Gostout CJ, Sorbi D, et al. Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest Endosc 2002; 56 (5): 657-62
33. Rudolph RE, Dominitz JA, Lampe JW, et al. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 2005; 14 (3): 605-8
34. Seike K, Koda K, Oda K, et al. Assessment of rectal aberrant crypt foci by standard chromoscopy and its predictive value for colonic advanced neoplasms. Am J Gastroenterol 2006; 101 (6): 1362-9
35. Stevens RG, Swede H, Heinen CD, et al. Aberrant crypt foci in patients with a positive family history of sporadic colorectal cancer. Cancer Lett 2007 Apr 18; 248 (2): 262-8
36. Bouzourene H, Chaubert P, Seelentag W, et al. Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. Hum Pathol 1999; 30 (1): 66-71
37. Siu IM, Pretlow TG, Amini SB, et al. Identification of dysplasia in human colonic aberrant crypt foci. Am J Pathol 1997; 150 (5): 1805-13
38. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005; 128 (1): 192-206
39. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256 (5053): 102-5
40. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346 (5): 311-20
41. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119 (5): 1219-27
42. Tagore KS, Lawson MJ, Yucaitis JA, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3 (1): 47-53
43. Petko Z, Ghiassi M, Shuber A, et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res 2005; 11 (3): 1203-9
44. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 2004; 126 (5): 1270-9
45. Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst 2005; 97 (15): 1107-9
46. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007; 16 (10): 1935-53
47. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104 (1): 66-73
48. Kozwich DL, Kramer LC, Mielicki WP, et al. Application of cancer procoagulant as an early detection tumor marker. Cancer 1994; 74 (4): 1367-76
49. Cordero OJ, Ayude D, Nogueira M, et al. Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer 2000; 83 (9): 1139-46
50. de la Haba-Rodriguez J, Macho A, Calzado MA, et al. Soluble dipeptidyl peptidase IV (CD-26) in serum of patients with colorectal carcinoma. Neoplasma 2002; 49 (5): 307-11
51. Kerber A, Trojan J, Herrlinger K, et al. The new DR-70 immunoassay detects cancer of the gastrointestinal tract: a validation study. Aliment Pharmacol Ther 2004; 20 (9): 983-7
52. Soroush AR, Zadeh HM, Moemeni M, et al. Plasma prolactin in patients with colorectal cancer. BMC Cancer 2004; 4: 97
53. Fedarko NS, Jain A, Karadag A, et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7 (12): 4060-6
54. Leman ES, Schoen RE, Weissfeld JL, et al. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 2007; 67 (12): 5600-5
55. Ward DG, Suggett N, Cheng Y, et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006; 94 (12): 1898-905
56. de Noo ME, Deelder A, van der Werff M, et al. MALDI-TOF serum protein profiling for the detection of breast cancer. Onkologie 2006; 29 (11): 501-6
57. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005; 5 (2): 142-9
58. Ransohoff DF. Colon cancer screening in 2005: status and challenges. Gastroenterology 2005; 128 (6): 1685-95
59. Zhao J, Qiu W, Simeone DM, et al. N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. J Proteome Res 2007; 6 (3): 1126-38
60. Zhu Y, Wu R, Sangha N, et al. Classifications of ovarian cancer tissues by proteomic patterns. Proteomics 2006; 6 (21): 5846-56
61. Tataryn DN, MacFarlane JK, Murray D, et al. Tube leukocyte adherence inhibition (LAI) assay in gastrointestinal (GIT) cancer. Cancer 1979; 43 (3): 898-912
62. Liu HP, Yan ZS, Zhang SS. The application of leukocyte adherence inhibition assay to patients with colorectal cancer: comparison with serum level of carcinoembryonic antigen and sialic acid. Dis Colon Rectum 1989; 32 (3): 210-3
63. Wang RF, Kim SJ, Robertson LH, et al. Development of a membrane-array method for the detection of human intestinal bacteria in fecal samples. Mol Cell Probes 2002; 16 (5): 341-50
64. Kopreski MS, Benko FA, Borys DJ, et al. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 2000; 92 (11): 918-23
65. Wang JY, Hsieh JS, Chang MY, et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg 2004; 28 (7): 721-6
66. Leung WK, To KF, Man EP, et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 2005; 100 (10): 2274-9
67. Umetani N, Kim J, Hiramatsu S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006; 52 (6): 1062-9
68. Bustin SA, Gyselman VG, Williams NS, et al. Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Br J Cancer 1999; 79 (11-12): 1813-20
69. Schiedeck TH, Wellm C, Roblick UJ, et al. Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzyme-linked immunosorbent assay. Dis Colon Rectum 2003; 46 (6): 818-25